SCHEMBL4515174

SCHEMBL4515174

CC(c1ccccc1)N1CCN(c2ccccc2)C1=O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.58
MEN1 O00255 1/20 0.58
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
CYP2D6 P10635 1/20 0.47
MAPK1 P28482 1/20 0.43
HSD11B1 P28845 2/20 0.43
MC4R P32245 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
DRD2 P14416 2/20 0.41
DRD3 P35462 2/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
OPRL1 P41146 1/20 0.41
KCNH2 Q12809 1/20 0.40
SIGMAR1 Q99720 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8026728 0.84 MEN1 (0.64) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL23909915 0.80 TRPC5 (0.37) KMT2AMEN1NPC1RAB9ACYP2D6
SCHEMBL23909922 0.80 TRPC5 (0.37) KMT2AMEN1NPC1RAB9ACYP2D6
SCHEMBL23909914 0.80 TRPC5 (0.37) KMT2AMEN1NPC1RAB9ACYP2D6
SCHEMBL8411315 0.79 MEN1 (0.56) KMT2AMEN1NPC1RAB9ACYP2D6
SCHEMBL11036674 0.78 MEN1 (0.55) KMT2AMEN1NPC1RAB9ADRD2
SCHEMBL11036717 0.77 MEN1 (0.50) KMT2AMEN1NPC1RAB9ADRD2
SCHEMBL610584 0.75 NPC1 (1.00) KMT2AMEN1NPC1RAB9ADRD2
SCHEMBL10887685 0.73 MEN1 (0.58) KMT2AMEN1NPC1RAB9ADRD2
SCHEMBL21348448 0.73 DRD2 (0.55) KMT2AMEN1NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 KMT2A 2379/4885MEN1 1254/4885NPC1 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.